Teva UK has launched GoResp Digihaler, which allows appropriate adult patients with asthma and COPD to help self-manage their condition and share their data with healthcare professionals.
The launch is the first of its kind in the UK and makes it the first country in Europe to make available the new inhaler system.
The GoResp Digihaler (budesonide/formoterol fumarate dihydrate) is an integrated device with built-in sensors to detect and record objective data on the patient’s use and ability to use their inhaler, including inspiratory flow classification.
Bluetooth technology allows the data collected by the inhaler to show on a connected patient app. Users can view and monitor their inhaler use and share the reports with their healthcare teams via an online healthcare professional dashboard, by email, or during face-to-face appointments.
Poor inhaler technique and erratic adherence to its use, both contribute to poor control of asthma. The use of the Teva digital inhaler system can help patients to better understand how they’re controlling their condition.
The connected app shows information on how well patients are inhaling their medication, based on an assessment of their inspiratory flow rate. It can also remind patients when to take their medication.
Kim Innes, general manager of Teva UK & Ireland said: “Providing key insights from viewing and monitoring inhaler technique and usage will support patients and healthcare professionals in the management of appropriate patients with asthma and COPD and represents an important step forward.
“This marks a major milestone for us as it extends our growing, innovative, respiratory portfolio as we continue on our mission to improve the lives of patients.”
Improving the use of asthma inhalers, has also recently been a focus for Suffolk Primary Care. Working with Aide Health, Suffolk Primary Care has launched a 12-month programme for asthmatic patients, designed to improve preventer inhaler use, and minimise the use of reliever inhalers.